XenoPort’s “Buy” Rating Reaffirmed at Jefferies Group (XNPT)
XenoPort (NASDAQ:XNPT)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group in a report issued on Tuesday, American Banking and Market News reports. They currently have a $6.00 price objective on the stock. Jefferies Group’s price target would indicate a potential upside of 45.63% from the stock’s previous close.
Shares of XenoPort (NASDAQ:XNPT) traded up 1.48% during mid-day trading on Tuesday, hitting $4.12. 352,540 shares of the company’s stock traded hands. XenoPort has a 1-year low of $3.88 and a 1-year high of $7.20. The stock has a 50-day moving average of $5.01 and a 200-day moving average of $5.53. The company’s market cap is $247.2 million.
XenoPort (NASDAQ:XNPT) last released its earnings data on Thursday, February 20th. The company reported ($0.40) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.45) by $0.05. The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $3.35 million. Analysts expect that XenoPort will post $-1.35 EPS for the current fiscal year.
Separately, analysts at Credit Suisse initiated coverage on shares of XenoPort in a research note on Friday, February 21st. They set an “outperform” rating and a $5.89 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $6.87.
XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.